

**60th American Society of Hematology Annual Meeting and Exposition  
San Diego, California – December 1-4, 2018  
Abstracts**

---

**MCRN-003 / CCTG MYX.1 - A Single Arm Phase II Study of High-Dose Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies**

**Time:** Saturday, December 1, 2018: 6:00 – 8:00 PM

**Location:** Hall GH (San Diego Convention Centre)

**Type:** Paper

**Session:** 653 - Myeloma: Therapy, excluding Transplantation: Poster I

**Presenter:** Christopher Venner

**Abstract:** ***A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies (#1984)***

**Authors:** *Christopher P. Venner, Richard Leblanc, Irwindeep Sandhu, Darrell J. White, Andrew R Belch, Donna E Reece, Christine I Chen, Sean Dolan, Andrea Kew, Marc Lalancette, Martha L Louzada, Arleigh McCurdy, Gail T. McDonald, Tony Reiman, Laura Rodriguez, Lois E. Shepherd, Engin Gul, Bingshu E. Chen, and Annette E. Hay*

**Link:** <https://ash.confex.com/ash/2018/webprogram/Paper117824.html>

---

**Alliance A041202 / CCTG CLC.2 – A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients ≥ 65 years of age) with Chronic Lymphocytic Leukemia (CLL)**

**Time:** Sunday, December 2, 2018: 2:00 – 4:00 PM

**Location:** Hall AB (San Diego Convention Center)

**Type:** Oral

**Session:** Plenary Scientific Session

**Presenter:** Frank G. Rucker

**Abstract:** ***Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202 (#6)***

**Authors:** *Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M Barr, Kerry A. Rogers, Sameer A. Parikh, Steven Coutre, Arti Hurria, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, Carolyn Owen, Jim Atkins, Jeremy S. Abramson, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J Mandrekar, and John C. Byrd*

**Link:** <https://ash.confex.com/ash/2018/webprogram/Paper116653.html>

---

---

**Alliance A10603 / CCTG ALC.2 - A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/ Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)**

**Time:** Sunday, December 2, 2018: 5:00 PM  
**Location:** Seaport Ballroom F (Manchester Grand Hyatt San Diego)  
**Type:** Oral  
**Session:** 613. Acute Myeloid Leukemia: Clinical Studies: Minimal Residual Disease and Genetic Characterization Hematology Disease Topics & Pathways: AML, Diseases, Adult, Study Population, Clinically relevant, Myeloid Malignancies  
**Presenter:** Frank G. Rucker  
**Abstract:** *Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (#435)*  
**Authors:** Frank G. Rücker, Ling Du, Tamara J. Blätte, Axel Benner, Julia Krzykalla, Insa Gathmann, Richard A. Larson, Francesco Lo-Coco, Sergio Amadori, Thomas W Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Michelle Geddes, Jorge Sierra, Eva Tiecke, Celine Pallaud, Miguel A. Sanz, Theo M de Witte, Dietger Niederwieser, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Lars Bullinger, Clara D. Bloomfield, Richard M. Stone, Hartmut Döhner, Christian Thiede, and Konstanze Dohner  
**Link:** <https://ash.confex.com/ash/2018/webprogram/Paper116149.html>

---

**CCTG LY.10 - A Phase II Study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) in Patients With Either Hodgkin's Disease or Aggressive Histology Non-Hodgkin's Lymphoma Which is Relapsed or Refractory**

**Time:** Sunday, December 2, 2018: 6:00 – 8:00 PM  
**Location:** Hall GH (San Diego Convention Centre)  
**Type:** Paper  
**Session:** 627 - Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster II  
**Presenter:** Mina Dehghani Mohammadabadi  
**Abstract:** *Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy - Analysis of Canadian Cancer Trials Group (CCTG) LY.10 Trial (#2980)*  
**Authors:** Mina Dehghani Mohammadabadi, Annette E. Hay, Lois E. Shepherd, Michael Crump, Bingshu E Chen, and Tara Baetz  
**Link:** <https://ash.confex.com/ash/2018/webprogram/Paper116316.html>

---